Find information on thousands of medical conditions and prescription drugs.

Eloxatin

Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as FOLFOX for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility. more...

Home
Diseases
Medicines
A
B
C
D
E
E-Base
Ecstasy (drug)
Edecrin
Edrophonium
Edrophonium chloride
Efavirenz
Effexor
Eflornithine
Elavil
Eldepryl
Elidel
Eligard
Elitek
Elixomin
Elixophyllin
Ellagic acid
Elmiron
Eloxatin
Elspar
Emtriva
Emylcamate
Enalapril
Enalaprilat
Enalaprilat
Endep
Enflurane
Enoxaparin sodium
Entacapone
Enulose
Epi-pen
Epinephrine
Epirubicin
Epitol
Epivir
Epogen
Eprosartan
Ergocalciferol
Ergoloid Mesylates
Ergotamine
Eryc
Eryped
Erythromycin
Esgic
Eskalith
Esmolol
Estazolam
Estazolam
Estrace
Estraderm
Estradiol
Estradiol
Estradiol valerate
Estring
Estrogel
Estrone
Estrostep
Ethacridine
Ethambutol
Ethchlorvynol
Ethosuximide
Ethotoin
Etiracetam
Etodolac
Etopophos
Etoposide
Etorphine
Evista
Exelon
Exemestane
Hexal Australia
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin®.

Side-effects

Side-effects of oxaliplatin treatment can potentially include:

  • Neuropathy, specifically including sensitivity to cold and numbness in the hands and feet
  • Fatigue
  • Nausea,vomiting, and/or diarrhea
  • Neutropenia
  • Hearing loss

In addition, some patients may experience an allergic reaction to platinum-containing drugs.

Read more at Wikipedia.org


[List your site here Free!]


Fast-track approval for cancer drug
From Nursing, 11/1/02

ELOXATIN

Approved by the FDA under a 46-day priority review process, Eloxatin (oxaliplatin) injection offers an alternative treatment for patients with advanced, refractory colorectal cancer. It's intended for use in combination with an infusion of 5-fluorouracil and leucovorin (5FU/LV) in patients whose disease has recurred or worsened following therapy with a combination of bolus 5-FU/LV plus irinotecan therapy. Eloxatin is also being evaluated for its benefits as a treatment for cancer-related symptoms, such as pain, weight loss, and fatigue, and for its effect on survival rates.

The approval of Eloxatin was based on an ongoing study of the safety and efficacy of the drug, alone and in combination with 5-FU/LV. The marketing application to the FDA, submitted to "rolling review" procedures set up for fast-track applications, was approved in just 7 weeks-the fastest yet for a cancer drug. Fast-track applications are reserved for drugs in development with the potential to be an advance in treatment for a serious illness.

Intended for use by clinicians experienced in cancer treatment Eloxatin is labeled with a "black box" warning highlighting possible anaphylactic-like reactions. The drug can have a toxic effect on nerve endings that may result in either an acute or cumulative pattern of adverse reactions, such as a feeling of numbness or tingling, especially in the hands or feet or around the mouth or throat This reaction usually occurs within hours or days of dosing. Patients may have trouble performing ordinary daily tasks, such as buttoning clothes; however, these problems generally improve after completion of treatment Diarrhea, vomiting, anemia, allergic reactions, bleeding, and infection are other potential adverse reactions.

Eloxatin is a product of Sanofi-Synthelabo.

Copyright Springhouse Corporation Nov 2002
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Eloxatin
Home Contact Resources Exchange Links ebay